Industry
Biotechnology
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Loading...
Open
2.20
Mkt cap
84M
Volume
8.5K
High
2.33
P/E Ratio
-1.25
52-wk high
4.48
Low
2.20
Div yield
N/A
52-wk low
1.93
Portfolio Pulse from Benzinga Insights
January 10, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 9:05 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2023 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2023 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2023 | 3:10 pm
Portfolio Pulse from Benzinga Insights
July 27, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Insights
July 26, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Insights
July 25, 2023 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.